Limited-time Discount: $49.9 Per Year
Limited-time offer: just $49.9! Early buyers enjoy full equal access to all iterative data updates for one year.
Vertical Industries Orthopedic Implants

Orthopedic Implants

01
China's Golden Track Spurred by Population Aging

Fueled by continuous advances in medical technology, surging orthopedic treatment demand amid population aging, and rising public health awareness, China's orthopedic device market is growing steadily. Its orthopedic implant market is forecast to top RMB 100 billion by 2029, implying enormous market potential.

02
Specialized Survey of Over 100 Enterprises

VCBeat carried out a specialized survey covering more than 100 relevant domestic enterprises. The platform screened participating companies from multiple dimensions including financing capacity, patent layout, approved products, cross-border collaborations and core teams. In addition, it sorted out the industrial structure based on core products and business focuses, and built a full-fledged industrial map of orthopedic implants.

03

Multi-dimensional Industrial Map of Orthopedic Implants

This map clearly illustrates the number of enterprises and core technical focuses within the four core segmented tracks. It also collates basic profiles of over 100 companies, including establishment date, business location, staff scale, contact details, official websites, financing history and corporate updates.

04
Full-spectrum Data Support & Collaboration

VCBeat has built in-depth connections with all enterprises on the map, offering exclusive cooperation channels and providing full-spectrum, authoritative data to support industrial planning, trend analysis, business collaboration and investment decision-making.

Industry Map

Trauma Implants (28)
More
Spine Implants (30)
More
Joint Reconstruction Implants (47)
More
Sports Medicine Implants (16)
More

Finance

VIEW ALL
Time
Company Name
Brief Introduction
Area
Funding rounds
Amount
June 24, 2026
Orthopedic Sports Medicine Product Developer
Guangdong,China
Series B
Tens of Millions of CNY
April 21, 2026
Tissue Engineering Bone Cartilage Regeneration Technology Developer
Shanghai,China
Series PreA
Nearly CNY 100M
April 03, 2026
Orthopedic Instrument R&D and Manufacturer
Beijing,China
Series C
CNY 150M
December 09, 2025
Developer and Manufacturer of Medical Materials and Devices
Hubei,China
Series A
CNY 2B
Time
Company Name
Brief Introduction
Area
Funding rounds
Amount
May 05, 2026
Provider of Comprehensive Clinical Solutions in Sports Medicine
Beijing,China
IPO
HKD 758.4M
February 10, 2026
Orthopedic Medical Device R&D and Supplier
Jiangsu,China
IPO
CNY 197M
December 30, 2021
Orthopedic Medical Device R&D and Manufacturer
Beijing,China
IPO
CNY 1.146B
June 30, 2021
Orthopedic Medical Device Manufacturer
Shandong,China
IPO
CNY 1.5B
May 21, 2021
High-end regenerative medical materials and implantable medical device R&D provider
Beijing,China
IPO
CNY 547.7M
April 09, 2020
Developer, Manufacturer, and Supplier of Medical Orthopedic Implants
Shanghai,China
IPO
CNY 978M
December 20, 2017
Orthopedic Implant R&D and Production Company
Hong Kong,China
IPO
Undisclosed
September 22, 2017
Developer and Manufacturer of High-Value Medical Consumables
Fujian,China
IPO
CNY 426.2M
March 11, 2015
Orthopedic Medical Device R&D and Manufacturer
Beijing,China
IPO
HKD 266M
June 13, 2012
Medical Device R&D, Production, and Sales Company
Shanghai,China
IPO
CNY 378M

Industry Insights

VIEW ALL
Finance
Medgen Secures Tens of Millions in Series B to Boost Regenerative Medical Materials Innovation
Leveraging its solid technological foundation and regulatory submission capabilities, Medgen has achieved market access breakthroughs for multiple core products. Its injectable artificial bone and oral bone graft substitutes have obtained Class III medical device registration certificates from the National Medical Products Administration in China, as well as Class D certification in Vietnam.
5min read
Read More
Innovation
J&J Upgraded — New Drug Approved in China, Q1 Revenue Beats
Johnson & Johnson reported Q1 2026 revenue of $24.06 billion, up 9.91% year-over-year, surpassing expectations and prompting an upward revision of full-year guidance. Leerink Partners upgraded J&J to 'Outperform' with a target price raised to $265, citing a robust pipeline of four blockbuster drugs, including an oral therapy projected to reach $10.5 billion in annual sales by 2032. On May 21, 2026, J&J announced that its FcRn antagonist Nicarlimab (An Li Wei) received NMPA approval in China for generalized Myasthenia Gravis, marking the first imported biologic under a domestic segmented production pilot program.
1min read
Read More
Innovation
Neo Modulus Makes Debut at ADA Forsyth Dentech Asia 2026 with FDA-Cleared Wenno® Gingival Repair Membrane
Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. showcased its proprietary Wenno® Gingival Repair Membrane at the inaugural ADA Forsyth Dentech Asia 2026 in Seoul, marking its second appearance at an ADA Forsyth event following a 2025 collaboration agreement. Now backed by U.S. FDA clearance and NMPA registration, Wenno® offers equivalent keratinized gingiva widening to the gold-standard Free Gingival Graft—without requiring autologous tissue—while improving procedural efficiency, patient comfort, and aesthetics. The company’s booth attracted global dental leaders, signaling Neo Modulus’s strategic shift from a Chinese innovator to a global player in regenerative dentistry.
2min read
Read More
Innovation
J&J's Myasthenia Gravis Drug Approved in China; Kelun-Biotech's TROP2 ADC Hits Primary Endpoint in Phase III TNBC Trial
Johnson & Johnson received NMPA approval for nipocalimab (Anliwei®), a fully human FcRn antagonist, for generalized myasthenia gravis in combination with standard therapy. Separately, Kelun-Biotech announced that its TROP2-targeted antibody-drug conjugate sacituzumab tirumotecan (Sac-TMT) met the primary endpoint of progression-free survival (PFS) in the Phase III OptiTROP-Breast03 trial as first-line treatment for unresectable recurrent or metastatic triple-negative breast cancer (TNBC), marking the first domestic TROP2 ADC to achieve a positive Phase III result in this setting.
2min read
Read More
Innovation
Sanyou Medical's Chunfeng Huayu Spine Surgery Robot Completes World's First Registered Clinical Trial Enrollment
Shanghai Sanyou Medical Co., Ltd. (688085.SH) announced that its affiliated company Chunfeng Huayu's spine surgery robot system has completed the world's first registered clinical trial enrollment at Nanjing Drum Tower Hospital as of May 18, 2026. The system, which has passed China's NMPA Innovative Medical Device Special Review Program, successfully performed a complex spine surgery under full physician supervision with multi-modal navigation guidance. Featuring proprietary multi-arm collaborative technology, the robot represents a significant milestone in intelligent orthopedic surgery and paves the way for upcoming commercialization.
1min read
Read More
In DepthIPO
Beijing-based sports medicine-focused Star Sports Medicine lists on HKEX
More than 30 years later, Beijing E-Town has grown into the core hub of Beijing's real economy. It features four major industrial clusters: new-generation information technology, high-end automobiles and new energy intelligent vehicles, biotech and big health, as well as robotics and intelligent manufacturing, with its total output value exceeding 600 billion RMB.
7min read
Read More
In DepthInsightInnovation
One approved, six on the way: is the pVAD market already becoming crowded in its first year of commercialization?
It should be noted that in invasive artificial hearts, higher flow support is not always better. Instead, multiple dimensions such as product size, support duration, and perfusion sealing technology need to be considered to provide tailored solutions for corresponding patients. For instance, the Impella series includes several models such as Impella CP, Impella 5.0, and Impella 2.5, offering different levels of maximum flow support at 3.7L/min, 5L/min, and 2.5L/min respectively, to meet the needs of different patients.
9min read
Read More
Startups
Star Sports Medicine Co.,Ltd.: Racing in the Sports Medicine Track at the Hong Kong Stock Exchange
Star Sports Medicine, a Chinese medical device manufacturer, achieved significant overseas revenue growth in the late autumn of 2024, with the first three quarters exceeding 38 million yuan. Despite facing pricing pressures from volume-based procurement policies, Star Sports Medicine successfully launched China's first all-suture anchor by independently developing core technologies, addressing industry pain points associated with traditional metal implants. Since its establishment in 2017, the company has gradually risen in the sports medicine market, capturing a 6.5% market share to become the fourth-largest player in China. Driven by both technological innovation and market expansion, Star Sports Medicine has continuously broken the monopolies of international giants, emerging as a leader in China’s high-end medical device industry. In 2026, the company once again submitted its application for a Hong Kong IPO. Capital support and technological innovation have been key factors in its success.
8min read
Read More
MNC China LensFinance
VCBeat Pharma Weekly | Novo Nordisk's long-acting growth hormone approved in China; Jacobio Pharma inks global deal with AstraZeneca
On December 22, AstraZeneca's Benralizumab Injection (brand name: Fasenra®, generic name: Benralizumab Injection) received approval from the China National Medical Products Administration (NMPA) for a new indication, for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA).
5min read
Read More
Finance
Yuanbao Biotechnology completes nearly 100 million Yuan in Series A financing, focusing on musculoskeletal regenerative medical materials R&D
Hangzhou Yuanbao Biotechnology Co., Ltd. Completes Nearly RMB 100 Million Series A FinancingHangzhou Yuanbao Biotechnology Co., Ltd. has completed nearly RMB 100 million in Series A financing, led by Hotang Ventures with participation from Zhejiang Venture Capital and others; financial advisory information was not disclosed. Yuanbao Biotechnology is a clinical-application-oriented enterprise specializing in the research and development of musculoskeletal regenerative medical materials. It was jointly established by Professor Fan Shunwu's orthopedic team from Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and the medical device industry. The proceeds from this round of financing will primarily be used to advance the clinical application of its core product, "Bone02 Bone Adhesive," which can rapidly bond in a blood-moist environment and achieve complete biodegradability. Additionally, the company’s representative products include a disposable gel patch former and porcine-derived bone repair materials. In the future, the bone adhesive is expected to be widely applied in various hard tissue bonding clinical scenarios.
2min read
Read More

Unlock to access premium whole insights

More Details
Research-led
Multiple Dimensions
Updated Quarterly
High-quality Chinese Assets Selected